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Yuan-Yang Lai, PhD,1* Yu-Hsuan Cheng, MS,1 Kung-Chiao Hsieh, PhD,1 Darian Nguyen, BS,1 Keng-Tee Chew, MS,1
Lalini Ramanathan, PhD,1 and Jerome M. Siegel, PhD1,2
1Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA
2Veterans Administration Greater Los Angeles HealthCare System, Sepulveda, Los Angeles, Los Angeles, California, USA
ABSTRACT: Background: Abnormal striatal
dopamine transmission has been hypothesized to cause
restless legs syndrome. Dopaminergic drugs are com-
monly used to treat restless legs syndrome. However,
they cause adverse effects with long-term use. An ani-
mal model would allow the systematic testing of poten-
tial therapeutic drugs. A high prevalence of restless legs
syndrome has been reported in iron-deficient anemic
patients. We hypothesized that the iron-deficient animal
would exhibit signs similar to those in restless legs syn-
drome patients.
Methods: After baseline polysomnographic record-
ings, iron-deficient rats received pramipexole injection.
Then, iron-deficient rats were fed a standard rodent
diet, and polysomnographic recording were performed
for 2 days each week for 4 weeks.
Results : Iron-deficient rats have low hematocrit levels
and show signs of restless legs syndrome: sleep frag-
mentation and periodic leg movements in wake and in
slow-wave sleep. Iron-deficient rats had a positive
response to pramipexole treatment. After the iron-
deficient rats were fed the standard rodent diet, hemato-
crit returned to normal levels, and sleep quality improved,
with increased average duration of wake and slow-wave
sleep episodes. Periodic leg movements decreased dur-
ing both waking and sleep. Hematocrit levels positively
correlated with the average duration of episodes in wake
and in slow-wave sleep and negatively correlated with
periodic leg movements in wake and in sleep. Western
blot analysis showed that striatal dopamine transporter
levels were higher in iron-deficient rats.
Conclusions: The iron-deficient rat is a useful animal
model of iron-deficient anemic restless legs syndrome.
VC 2017 International Parkinson and Movement Disorder
Society
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Restless legs syndrome (RLS) is a sensory-motor dis-
order1,2 characterized by unpleasant and painful sen-
sations and is usually accompanied by paresthesias.
These uncomfortable sensations occur during rest or
while lying down, typically appear in the late after-
noon or evening, and are relieved by movement. Thus,
RLS patients suffer from the inability to fall asleep
and stay asleep, resulting in profound insomnia.3 Rest-
less legs syndrome has been reported in patients with
iron-deficient (ID) anemia,4 Parkinson’s disease,5,6 and
end-stage renal disease,7 as well as in children with
attention deficit hyperactivity disorder8 and in preg-
nant women.9 Despite RLS disorder occurring in all
age groups and affecting 5%-10% of the population,
making it one of the most common movement disor-
ders,10 there is no satisfactory treatment and no suit-
able animal model that would allow the development
of better treatments.
The subjective abnormal sensations have made it
difficult to develop an animal model of RLS. How-
ever, periodic leg movements (PLMs), an objective
motor event, can be recorded in animals. PLMs in
quiet wake is common in RLS patients.11,12 More
than 85% of RLS patients also have PLMs in sleep.13
Clinical studies have shown a high prevalence of RLS
in ID anemic patients.14 Neural abnormalities in the
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Restless legs syndrome (RLS) is a sensory-motor dis-
order1,2 characterized by unpleasant and painful sen-
sations and is usually accompanied by aresthesias.
These uncomfortable sensations occur during rest or
w ile lying down, typically appear in the late after-
noon or evening, and are relieved by movement. Thus,
RLS patients suffer from the inability to fall asleep
and stay asleep, resulting in profound insomnia.3 Rest-
less legs syndrome has been reported in patients with
iron-deficient (ID) anemia,4 Parkinson’s disease,5,6 and
end-stage renal disease,7 as well as in children with
attention deficit hyperactivity disorder8 and in preg-
nant women.9 Despite RLS disorder occurring in all
age groups and affecting 5%-10% of the population,
making it one of the most common movement disor-
ders,10 there is no satisfactory treatment and no suit-
able animal model that would allow the development
of better treatments.
The subjective abnormal sensations have made it
difficult to develop an animal model of RLS. How-
ever, periodic leg movements (PLMs), an objective
motor event, can be recorded in animals. PL s in
quietwake is common in RLS patients.11,12 ore
l
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substantia nigra and abnormal sleep architecture have
been reported in ID rats and mice, respectively.15,16
However, motor activity in quiet wake and in sleep, a
key element of restless legs syndrome, has not been
studied in ID animals. In this study, we examine
whether ID rats have abnormal sleep patterns and
motor activity, using video and polysomnographic
recording techniques. Abnormal striatal dopamine
transmission — increased, decreased, or unchanged
dopamine transporter (DAT) level — has also been
reported in idiopathic RLS patients.17-19 Thus, we
have measured striatal DAT levels in ID rats com-
pared with control rats, using the Western blot
technique.
Methods
All procedures were approved by the Institutional
Animal Care and Use Committee of the VA Greater
Los Angeles Healthcare System.
Development of Iron-Deficient Rat
Thirteen Sprague-Dawley weanling rats (21 days
old) were purchased from Charles River Laboratory
and then divided into 2 groups: 6 normal controls and
7 iron-deficient (ID) rats. Control rats were fed with
standard rodent diet containing 35 ppm iron, whereas
ID rats were fed with a rodent diet containing 4 ppm
iron (TD.80396; Harlan Teklad Lab) for 2 months.
All rats were then surgically implanted with electrodes
for sleep and motor activity recordings.
Surgery
Implantation of electrodes for electroencephalograph
(EEG) and electromyograph (EMG) recordings in the
animal was described in our previous study.20 Briefly,
under isoflurane (1.5%) anesthesia, 3 jeweler’s screw
electrodes were implanted over the cortex (A, anterior
to lambda; L, lateral from the midline; A14, L2.5;
A10, L 3.5; and A5, L1) for cortical EEG recording.
Flexible multistranded stainless steel wires (793500;
A-M Systems, Inc., Carlsborg, WA) were inserted into
the nuchal and hindlimb musculature bilaterally and
routed subcutaneously to the skull for EMG record-
ing. Wires from all electrodes were soldered to a 14-
pin Amphenol strip connector and encased in an
acrylic head plug.
Polysomnographic and Video Recordings
Animals were allowed to recover from surgery for a
week. Animals were individually housed in sound-
attenuated chambers with a 12:12 light-dark cycle
and ad libitum access to food and water. Electrophysi-
ological signals were collected and amplified through a
polygraph (model 15LT; Grass, MA) and then
digitized and recorded via a Micro 1401 interface
(Cambridge Electronics Design, Cambridge, UK).
Sleep and phasic leg movements were visually scored
offline with a tailored script in Spike2 (Cambridge
Electronics Design, Cambridge, UK). Infrared cameras
were used for video recordings. Video images were
captured digitally through a 4-channel surveillance
video recorder card (Q-See QSPDVR04; RapidOS,
New Taipei City, Taiwan). Video was recorded con-
tinuously with time stamps matched to polysomno-
graphic recordings.
Pramipexole Injection
After 3 days of baseline polysomnographic record-
ings, 5 each control and ID rats were systemically
(intraperitoneally) administered saline or 3 doses
(0.01, 0.02, and 0.05 mg/kg) each of pramipexole at
Zeitgeber (ZT) 2. Sleep and motor activity recordings
were continued for 8 hours after saline or test drug
injection.
Iron-Replacement Experiment
After saline and test drug injection experiments, ID
rats were fed standard rodent diet containing 35 ppm
iron for up to 4 weeks. Sleep and motor activity
recordings resumed on day 6 post–standard rodent
diet feeding. Sleep recordings were performed for 2
days continuously each week, for an additional 3
weeks.
Hematocrit Measurement
Blood was collected from the lateral tail vein, trans-
ferred into a heparinized hematocrit capillary, and
centrifuged at 10,000 rpm for 3 minutes in a hemato-
crit centrifuge (BD Clay Adams 420563). Hematocrit
levels were calculated by measuring the length of the
red blood cell layer against the total blood layer.
At the end of the experiment, all rats were deeply
anesthetized with isoflurane and their brains removed.
The striatum was dissected and stored at -808C.
Western Blot Experiment
The striatum was separately sonicated in lysis buffer
(50 mM Tris, 5 mM EDTA, 30% igepal NP-40, 10%
Na deoxycholate, and 1% sodium dodecyl sulfate [pH
7.5]) and protease inhibitor tablet (Roche 4693124)
and then centrifuged at 10,000g for 20 minutes at
48C. Protein concentration of the supernatant was
determined using a DC protein assay kit (BioRad 500-
0112) and read at 650 nm in an Emax Precision micro-
plate reader (Molecular Devices) using a Softmax pro-
gram. Ten micrograms of striatal protein was loaded
on a 10% mini-protean TGX precast gel (Biorad 456-
1034) and electrophoresed for 1.5 hours at room tem-
perature at 120 V. Proteins were then transferred to a
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polyvinylidene fluoride membrane for 1.5 hours at
100 mA at room temperature. Membranes were
washed in Tris-buffered saline with tween (TBST: 20
mM Tris, 150 mM NaCl, 0.1% tween) and then
blocked in TBST containing 5% nonfat dry milk for 1
hour at room temperature. Membranes were subse-
quently incubated with rabbit anti-DAT (1:2,000;
Millipore AB2231), and mouse antiactin (1:10,000;
Millipore MAB1501R) overnight at 48C, goat antirab-
bit IgG conjugated with horseradish peroxidase (HRP;
1:10,000; Jackson Immunores Lab 111-035-144) and
goat antimouse IgG conjugated with HRP (1:10,000,
Jackson Immunores Lab, 715-035-140) for 1 hour and
West Femto (1:80; Thermo Scientific 34094) for 5
minutes. Membranes were washed 3 times of TBST
between incubations. Dopamine transporter (75 KDa)
and actin (43 KDa) were detected and visualized using
a ChemiDoc XRS1 system (Biorad). Striatal proteins
obtained from the normal control, ID, iron replace-
ment week 1 (IR1), week 2 (IR2), week 3 (IR3), and
week 4 (IR4) rats were analyzed simultaneously on
the same gels and blots.
Data Analysis
The CED 1401 Spike 2 program was used to ana-
lyze EEG power spectra, as well as to detect and score
phasic motor activity during quiet wake and sleep.
Periodic leg movements in quiet wake (PLMW) and in
slow-wave sleep (SWS; or nonrapid eye movement
sleep) (PLMS) were analyzed by adapting the criteria
outlined by the World Association of Sleep Medicine
standards for scoring PLM.21 In brief, phasic motor
events (jerks) in the leg, satisfying the following crite-
ria, were counted as PLMs: (1) the amplitude of the
jerk was twice the tonic background; (2) the duration
of the jerk ranged between 0.2 and 5 second; (3) the
interval between jerks was less than 90 seconds; and
(4) at least 4 consecutive jerks fulfilled criteria 1-3.
Phasic motor events, which did not meet criterion 4 of
PLM in SWS, were counted as isolated leg movements
in sleep (ILMS). The index of PLM in quiet wake
(PLMWI) and in SWS (PLMSI) was calculated as the
total number of periodic motor movements divided by
total time in quiet wake or in SWS, respectively. Simi-
larly, the index of ILMS (ILMSI) was calculated as the
total number of ILMS divided by total time in sleep.
To determine the density of dopamine transporter in
the striatum, the optical density of the dopamine
transporter band was measured using Quantity One 1-
D analysis software (Biorad). Relative levels of striatal
dopamine transporter in each animal were obtained
by measuring the ratio of the optical density of dopa-
mine transporter and actin.
One-way ANOVA with replicated measures fol-
lowed by a Bonferroni’s post hoc, t-test and Pearson
correlation test were used for statistical analysis.
Results
Hematocrit Levels, Sleep Patterns, and Motor
Activity in Control and Iron-Deficient Rats
Average hematocrit level of normal rats was 47.1 6
0.2, whereas hematocrit levels of ID rats were signifi-
cantly lower, at 20.6 6 3.2 (P < 0.001, df 5 11, t
test; Table 1).
Neither the percentage of SWS (P > 0.05, df = 11,
t-test; Table 1), nor the percentage of wake (P > 0.05,
df 5 11, t test; Table 1) in ID rats was different from
control rats. In contrast, the percentage of REM sleep
was lower in ID rats than in control rats (P < 0.05, df
5 11, t test; Table 1). Sleep fragmentation was
observed in ID rats. Statistical analysis showed that
the daily average duration of a waking episode (P <
0.01, df 5 11, t test; Table 1) and an SWS episode (P
TABLE 1. Hematocrit levels, percent of wake-sleep stages, average duration (minutes) of sleep-wake episodes, and motor
activity in normal control, iron-deficient, and iron-replacement rats
Hct
Percent of sleep-wake stagesa Average duration of episodea Motor activitya
Wakeb SWSb REMb Wakeb SWSb REMb PLMSI PLMWI ILMSI
C 47.1 6 0.1c 49.5 6 2 44.5 6 1.7 6 6 0.9 1.95 6 0.35a 1.67 6 0.31c 1.1 6 0.13 7.8 6 2.6c 0c 18.8 6 5.5
ID 25.2 6 1.5c,d 49.7 6 3.9 45.6 6 3.2 4.7 6 1c,d 1.41 6 0.13c,d 1.28 6 0.21c,d 1.21 6 0.27 49.8 6 16.9c,d 14 6 29.4c 16.9 6 2.2
IR1 38.7 6 1.1d,e 47.7 6 1.3 46.1 6 1 6.2 6 0.9 1.97 6 0.17d 1.79 6 0.2d 1.27 6 0.17 18.5 6 6.9d,e 5.8 6 6.9 18.6 6 3.9
IR2 41 6 0.6d,e 46.3 6 2.9e 47.3 6 2.2e 6.4 6 1d 1.95 6 0.13d 1.87 6 0.18d 1.31 6 0.23 9.3 6 6.4d 2.7 6 3.8 17.6 6 7.7
IR3 44.8 6 0.3d,e 46 6 4e 47.9 6 3.5e 6.1 6 1 2.02 6 0.3d 1.98 6 0.24d 1.22 6 0.21 6.8 6 4d 1.4 6 1.7 18.5 6 5.3
IR4 47.2 6 0.1d,e 46.2 6 3.2e 47.9 6 2.8e 5.9 6 0.8 1.98 6 0.2d 1.96 6 0.24d 1.23 6 0.23 4.6 6 4.6d 1 6 1.5 18 6 6.2
Number of animals — control, 6; ID and IR1-IR4, 7 each.
Hct, hematocrit level; W, wake; SWS, slow-wave sleep; REM, rapid eye movement sleep; PLMSI and PLMWI, index of periodic leg movements in sleep and in
quiet wake, respectively; ILMSI, index of isolated leg movements in sleep; C, normal control rat; ID, iron-deficient rat; IR1-IR4: ,iron replacement (IR) rats fed
with standard rodent diet for 1, 2, 3, or 4 weeks.
aData (mean 6 SD) taken from 24-hour recording.
bMinutes.
cSignificant difference between ID and control rats.
dSignificant difference between ID and IR rats.
eSignificant difference between IR and control rats;.
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< 0.05, df 5 11, t test; Table 1) was shorter in ID
rats than in control rats.
Motor hyperactivity in wake and in SWS was
observed in the ID rats. Periodic leg movements in
wake, which were not seen in control rats and in 2 ID
rats, were observed in 5 ID rats. Periodic leg move-
ments in wake were often seen immediately before the
animal fell asleep (Fig. 1). A very high amount of
PLM in sleep (see the video) was seen in ID rats. PLM
occurred in one (Fig. 1A) or both (Fig. 1B) hindlimbs
in all ID rats. The PLMWI (P < 0.001, df 5 11, t
test; Table 1) and PLMSI (P < 0.001, df 5 11, t test;
Table 1) in ID rats were significantly higher than in
normal rats. PLMWI and PLMSI were significant
higher in ID rats than in control rats in both the light
phase (PLMWI: df 5 11, t test, P < 0.001; PLMSI: df
5 11, t test, P < 0.001) and dark phase (PLMWI: df
5 11, t test, P < 0.001; PLMSI: df 5 11, t test, P <
0.001). However, isolated leg movements in sleep did
not differ between control and ID rats (df 5 11, t test,
P 5 0.19; Table 1).
Effect of Pramipexole Treatment on Sleep and
Motor Activity in ID Rats
Intraperitoneal injection of pramipexole, a dopamine
D3 agonist and commonly used for the treatment of
RLS, decreased PLM in sleep (df 5 4, ANOVA; P <
0.001) during 8 hours of recording after injection
(Table 2) in ID rats. Post hoc analysis showed that pra-
mipexole dose dependently decreased PLM in sleep.
Although PLM in wake was decreased by pramipexole
injection, the change in PLM in wake was not signifi-
cant (Table 2). The sleep-wake pattern was not changed
by any dose of pramipexole injection (Table 2).
Hematocrit Level, Sleep Pattern, and Motor
Activity in Iron-Deficient Rat After Iron
Therapy
Hematocrit level, sleep quality, and motor activity
were dramatically changed starting during the first
week of iron replacement. After 4 weeks of iron
replacement, ID rats showed a significant increase in
hematocrit level (ID vs IR1, IR2, IR3, and IR4, post
hoc test, P < 0.001; Table 1) and a significant increase
in REM sleep (df 5 4, ANOVA, P 5 0.001; Table 1).
Although wake (df 5 4, ANOVA, P 5 0.08; Table 1)
and SWS (df 5 4, ANOVA, P 5 0.25; Table 1) times
were not changed, the average duration of episodes in
wake (ID vs IR1, IR2, IR3, and IR4, post hoc test, P
< 0.001; Table 1) and in SWS (ID vs IR1, IR2, IR3,
and IR4, post hoc test, P < 0.001; Table 1) was sig-
nificantly increased after iron replacement. Duration
of bouts of both wake and SWS in ID rats reached
control levels in week 1 post–iron replacement (Table
1). Furthermore, both the average bout duration in
wake (R2 5 0.91, n 5 32, Pearson correlation test, P
< 0.01) and in SWS (R2 5 0.77, n 5 32, Pearson cor-
relation test, P < 0.05) were positively correlated with
hematocrit level.
Motor hyperactivity that was seen in ID rats was
also improved after iron replacement. Periodic leg
movements in SWS (ID vs IR1, IR2, IR3, and IR4,
post hoc test, P < 0.01; Table 1) were significantly
decreased after the ID rat was fed standard rodent
diet compared with ID rats on a low iron diet. The
occurrence of PLM in sleep was reduced to control
levels in week 2 post–iron replacement (Table 1).
Although PLM in wake showed no change in 24 hours
(df 5 4, ANOVA, P 5 0.14), a significant decrease
was observed in the light phase (df 5 4, ANOVA, P
< 0.05) after iron replacement. We also found that
hematocrit levels were negatively correlated with PLM
in sleep (R2 5 20.99, n 5 32, Pearson correlation
test, P < 0.001) and in wake (R2 5 20.99, n 5 32,
Pearson correlation test, P < 0.001). In contrast, the
ILMSI in ID rats was not changed after iron replace-
ment (df 5 4, ANOVA, P 5 0.77).
Striatal Dopamine Transporter Levels in
Control, Iron-Deficient, and Iron-Replacement
Rats
Striatal dopamine transporter levels were higher in
the ID rat than the control and IR rats (Fig. 2). The
increased striatal dopamine transporter levels were
decreased to the control level 1 week after the ID rat
was fed a standard rodent diet (Fig. 2). Striatal dopa-
mine transporter levels were negatively correlated with
hematocrit levels (R2 5 -0.98, n 5 32, Pearson corre-
lation test, P < 0.001) and positively correlated with
PLM in sleep (R2 5 0.98, n 5 32, Pearson correlation
test, P < 0.001) and in wake (R2 5 0.99, n 5 32,
FIG. 1. Periodic leg movements in the right (A) or both the right and
left (B) hindlimbs, in wake, before the animal falls asleep. Periodic leg
movements were not observed in sleep (A), whereas PLM was gradu-
ally diminished in sleep (B). LegL and LegR, left and right hindlimb
EMG.
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Pearson correlation test, P < 0.01) in a 24-hour
recording.
Discussion
We found that ID rats exhibit sleep fragmentation,
motor hyperactivity, PLM in quiet wake, and an
increase in PLM in sleep, signs resembling those in
human RLS patients. We also found that iron therapy
improved PLM in quiet wake and in sleep, hematocrit
levels, and sleep quality. Furthermore, we found that
hematocrit levels are negatively correlated with PLM
in wake and in sleep, as well as positively correlated
with average wake and SWS bout duration. Western
blot studies showed that striatal dopamine transporter
levels were higher in ID rats than in normal control
and iron-replacement rats, suggesting abnormal stria-
tal dopamine transmission may contribute to motor
hyperactivity in ID rats. The ID rat had a positive
response to pramipexole treatment, indicating the
ID rat is a useful animal model of ID anemic-induced
RLS.
Using polygraphic recording simultaneously with
real-time video recording, we were able to observe and
record behavioral activities. An increase in PLM in
sleep was observed in all ID rats. Montplaisir et al13
reported that 80% of RLS patients had PLM in sleep.
The difference in RLS patients and ID rats in PLM in
sleep may be because of the unique factor (low hemato-
crit level) in ID rats. However, PLM in wake was not
observed in 2 of 7 ID rats. Montplaisir et al reported
that 20% of RLS patients did not show PLM in the
immobilization test.22 The ID rat without PLMs in
wake may not have abnormal sensations and/or urge to
move; however, they have PLM disorder.
Clinical studies have shown inconsistent responses
of motor activity to iron therapy in RLS patients, with
a decrease in PLM in sleep23,24 or no change in PLM
in sleep or in wake.25 In our study, we found that
PLM in sleep decreased after ID animals are fed a
standard rodent diet, which contains 35 ppm iron.
The decrease in PLM and increase in hematocrit levels
were most profound after the first week of iron
replacement. Although PLM in wake was also
decreased after the iron therapy, the decrease in PLM
in wake was not significant. This may be because of
the high variation of the baseline, which included data
from 2 ID rats without PLM in wake. Isolated leg
movements in sleep were not affected by iron therapy.
However, a significant decrease in PLM in wake was
found in the light phase after iron therapy, as well as
during pramipexole treatment (Table 2) in the light
phase, indicating the animal awakening from sleep less
frequently.
In the present study, we found that iron deficiency
decreases REM sleep and causes sleep fragmentation
and a shorter duration of wake and SWS episodes.
These sleep disorders can be reversed by iron replace-
ment. Decreased PLM in sleep and increased SWS
bout duration indicate that iron-replacement animals
awaken less often, resulting in more consolidated
TABLE 2. Effect of intraperitoneal injection of saline or pramipexole on sleep and motor activitya
Sleep-wake states (minutes) Motor activity
Wakeb SWSb REMb PLMSI PLMWI ILMSI
Baseline 176.7 6 24.4 274.6 6 21.5 28.6 6 8.3 55.5 6 18.8 12.8 6 17.4 14.3 6 3.5
Saline 167.6 6 10.8 279.5 6 13.9 32.9 6 5.7 50.2 6 15.8 19.3 6 17.7 14.9 6 3.5
Pramipexole
(mg/kg)
0.01 166.9 6 40.8 284.3 6 38.6 28.8 6 8 25.6 6 5.6c,d,e 14 6 20.9 20.2 6 2.7c
0.02 194.3 6 38.4 259 6 28.7 26.7 6 12.9 18.2 6 4.1c,d,f 3.7 6 2.9 19 6 3.6c
0.05 200.9 6 63.3 249.2 6 56.4 29.9 6 9.6 14.3 6 4.2c,d,e 1.8 6 1.5 22.1 6 6.1
aData (mean 6 SD) taken from the average of 8-hour recordings after saline or drug injection at ZT2. n 5 5 each, post hoc test.
bMinutes/8 hours.
cBaseline versus drug injection, P < 0.05.
dSaline versus drug injection, P < 0.05.
ePramipexole 0.01 versus 0.02 or 0.05 mg/kg, P < 0.05.
fPramipexole 0.01 versus 0.02 mg/kg.
FIG. 2. Striatal dopamine transporter (DAT) in the control (C), iron-
deficient (ID), and iron-replacement week 1 (IR1), week 2 (IR2), week 3
(IR3), and week 4 (IR4) rats. Top: example of Western blot showing
striatal DAT and actin expression in samples taken from control, ID
and IRs rats. Lower: relative density of bands expressed as the ratio
of DAT and actin in each animal groups. *P < 0.05, t test; **P < 0.01, t
test. n 5 5 each group.
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sleep. Dean et al15 reported that total sleep time over
24 hours and during the light and dark periods did
not differ between ID and normal mice. However,
they did observe significantly increased wake and sig-
nificantly decreased SWS during the last 4 hours of
the dark phase in ID mice.15 We did not observe
changes in total amount of sleep or wake time in ID
compared with normal rats in any period, including
the last 4 hours of the dark phase (data are not
shown). There may be a species difference in altered
sleep architecture.
Eisensehr et al17 and Conner et al16 reported that the
concentration of the striatal dopamine transporter did not
differ between drug-naive and levodopa-treated idiopathic
RLS patients and controls. On the other hand, Earley
et al18 showed that dopamine transporter at the neuronal
membrane of the striatum is decreased in RLS patients. In
contrast, Kim et al19 found an increase in striatal dopa-
mine transporter in elderly RLS patients. The dopamine
transporter has been shown to control dopamine trans-
mission through reuptake of extracellular dopamine into
presynaptic neuron. Thus, the increased DAT may
decrease the spatial and temporal dynamic of dopamine
to bind and activate dopamine D2 receptor, which in turn
produces motor hyperactivity,26 as seen in the ID rat.
In addition to the abnormality in the central nervous
system, peripheral neuropathy may also contribute to
motor hyperactivity in ID rats. A sensory fiber abnor-
mality has been reported in RLS patients.27-30 Clinical
studies showed a high prevalence of RLS in patients
with celiac disease31 and multiple sclerosis,32 who have
iron-deficiency anemia33,34 and peripheral neuropa-
thy.35,36 Peripheral nerve conduction velocity has been
found to be positively correlated with hemoglobin and
hematocrit levels.37,38 Indeed, ID anemic patients have
lower peripheral nerve conduction velocity than normal
controls, and this peripheral neuropathy can be normal-
ized by iron supplements.37,38 Thus, mechanisms under-
lying motor hyperactivity caused by iron deficiency and
improved PLM in sleep and in wake from iron replace-
ment, which were seen in the present study, may also
occur via the peripheral nervous system.
In conclusion, we found that ID rats have signs of
RLS, including sleep fragmentation and motor hyper-
activity in wake and in sleep. Hematocrit levels and
sleep quality were improved and motor hyperactivity
was reversed after ID rats were treated with iron.
Motor hyperactivity in ID rats can also be corrected
by systemic administration of pramipexole. Although
the majority of the RLS is not caused by iron-
deficiency anemia, the ID rat can serve as an animal
model of ID anemic-induced RLS. This animal model
will allow us to study mechanisms underlying the
motor component of ID anemic-induced RLS, as well
as to test potential drugs for the better treatment of
ID anemic-induced RLS.
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